Tecartus denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for tecartus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Apply Step Therapy to Tecartus

Tecartus (brexucabtagene autoleucel) is a CAR-T cell therapy used for certain relapsed or refractory hematologic malignancies. BCBS's step therapy (also called "fail-first") policies require documentation that specific prior lines of therapy were attempted before an advanced or high-cost treatment is approved. For Tecartus, step therapy is particularly significant because the FDA-approved label itself specifies a prior-therapy requirement — meaning demonstrating completed steps is both a BCBS policy requirement and a clinical eligibility requirement. Denials in this category are very frequently overturned when prior treatment history is thoroughly documented.

## Federal Appeal Rights

• Internal appeal: Under ERISA §503 and ACA §2719, you are entitled to a full-and-fair internal review. Many states also have step-therapy override laws that may provide additional protections; check whether your state's law applies to your plan type.
• External review: Independent external review is available after exhausting internal appeal — typically within approximately four months of a final internal denial under ACA-compliant plans.
• Expedited review: Request expedited review (72-hour timeline) if your oncologist documents that completing additional therapy steps would seriously jeopardize your health given disease progression.

## What to Include in Your Appeal

1. Chronological treatment history: A dated, comprehensive list of every prior line of therapy — including drug name, start and end dates, doses, and documented response or reason for discontinuation — directly mapped to the step requirements in BCBS's policy and the FDA label. 2. Medical records supporting each step: Clinic notes, infusion records, lab results, and imaging that confirm each prior therapy was administered and the outcome. 3. Documentation of inadequate response or contraindication: If prior steps failed due to toxicity, intolerance, or disease progression, include the clinical documentation. 4. Prescriber medical-necessity letter: Your oncologist should explain why further step therapy is not appropriate and why Tecartus is now indicated, referencing the FDA label and applicable NCCN guideline language. 5. Step-therapy override request: If your state has enacted step-therapy override protections, cite the applicable statute in your appeal letter.

## Criteria-Mapping Structure

| Step-Therapy Requirement (from BCBS policy and FDA label) | Your Documentation | |---|---| | Prior therapy type(s) required | Treatment history with dates | | Duration or adequacy of prior therapy | Infusion records, clinic notes | | Documented failure, intolerance, or progression | Labs, imaging, clinical notes | | Clinical reason to bypass remaining steps | Prescriber letter |

## Next Step

Obtain the current BCBS step-therapy criteria for Tecartus from their published medical policy. Build a side-by-side table matching every step to your chart records before submitting. The treating CAR-T center's patient services team routinely assists with these appeals and may already have a standard documentation package.